Pharmaceuticals New Zealand

New Zealand COPD Treatment Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

New Zealand COPD Treatment Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Device, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

New Zealand · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $260.0 Mn Placeholder estimate
Estimate 2025 $270.1 Mn 1.1% of the global market
Projected 2034 $381.1 Mn 41.1% Adds $111.0 Mn over 9 forecast years
CAGR 2025–2034 3.9% Faster than 5% of 160 Pharmaceuticals markets here
Key players 5
  • New Zealand is 1.14% of the global market.
  • In APAC, the largest is China at $2.16 Bn.
  • Fastest growing: India at 7.3% a year.
  • New Zealand ranks 5th of 10 by size in APAC.

Market size projection

New Zealand

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$111.0 Mn total, 2026–2034

Year-by-year market size, 2024–2034
COPD Treatment Market market size by year, New Zealand
YearMarket sizeChange that yearSince 2025
2024 (estimate) $260.0 Mn — —
2025 (base) $270.1 Mn +$10.1 Mn —
2026 (forecast) $280.6 Mn +$10.5 Mn +3.9%
2027 (forecast) $291.6 Mn +$10.9 Mn +8%
2028 (forecast) $302.9 Mn +$11.4 Mn +12.2%
2029 (forecast) $314.8 Mn +$11.8 Mn +16.5%
2030 (forecast) $327.0 Mn +$12.3 Mn +21.1%
2031 (forecast) $339.8 Mn +$12.8 Mn +25.8%
2032 (forecast) $353.0 Mn +$13.3 Mn +30.7%
2033 (forecast) $366.8 Mn +$13.8 Mn +35.8%
2034 (forecast) $381.1 Mn +$14.3 Mn +41.1%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

New Zealand COPD Treatment Market Analysis at a glance
Market size, 2025$270.1 Mn placeholder estimate
Forecast, 2034$381.1 Mn placeholder estimate
Growth (CAGR), 2025–20343.9% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug class, device and end user (see all)
Key playersGSK PLC, AstraZeneca, Boehringer Ingelheim GmbH, Sanofi, Verona Pharma (see all)
Regulator in New ZealandMedsafeSource: Medsafe. Checked 14 Nov 2026.
Active clinical trials9 in New ZealandSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in New Zealand. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The New Zealand COPD Treatment Market Analysis Executive Summary

COPD treatments help people with chronic obstructive lung disease breathe more easily and have fewer flare-ups.

Key segments of the COPD Treatment market include drug class (LAMA/LABA Combinations, Triple Therapy and Biologics) and device (Dry Powder Inhalers, Metered Dose Inhalers and Nebulizers).

Bar chart: New Zealand COPD Treatment market size, 2024–2034, placeholder estimates. $260.0 Mn in 2024, $270.1 Mn in 2025 and $381.1 Mn in 2034, 3.9% CAGR.
New Zealand COPD Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

New Zealand COPD Treatment Market Dynamics

Market Growth Drivers

Rising rates of chronic disease linked to diabetes, ageing, smoking and pollution, plus new treatments that slow disease, are driving the COPD Treatment market.

Opportunity

Earlier screening, new drug classes and home-based care give the COPD Treatment market room to grow.

Market Restraints

Late diagnosis, high prices of new medicines, limited specialist care and poor adherence hold back the COPD Treatment market.

Competitive Landscape for COPD Treatment Market in New Zealand

The COPD Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for COPD Treatment Market in New Zealand

COPD Treatment in New Zealand: rules, payment and research

Medsafe, part of the Ministry of Health, approves medicines before they can be sold.⁠[1] Pharmac decides which medicines and medical devices the public health system pays for.⁠[2] ClinicalTrials.gov lists 9 studies on COPD Treatment that are recruiting, active or about to start in New Zealand.⁠[3]

[1] Medsafe. Checked 14 Nov 2026.

[2] Pharmac. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in New Zealand. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for COPD Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in New Zealand.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in COPD Treatment right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

COPD Treatment in context

New Zealand compared

  • Health spending per person: 5,022 US$ per person (2024). World: 1,317 US$ per person (2023). 2nd highest of the 17 countries we cover in APAC.[1]
  • Doctors: 3.61 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 2nd highest of the 17 countries we cover in APAC.[2]
  • People aged 65 and over: 17.6% of people (2025). World: 10.4% of people (2025). 5th highest of the 18 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 19 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 19 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 19 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the COPD Treatment market in New Zealand?
Placeholder estimate: about $270.1 Mn in 2025, rising to about $381.1 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the COPD Treatment market in New Zealand growing?
Placeholder estimate: about 3.9% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the COPD Treatment market report cover?
The report splits the market by drug class (LAMA/LABA Combinations, Triple Therapy, Biologics, PDE4 Inhibitors), device (Dry Powder Inhalers, Metered Dose Inhalers, Nebulizers) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the COPD Treatment market?
Key players include GSK PLC, AstraZeneca, Boehringer Ingelheim GmbH, Sanofi and Verona Pharma.
What is driving the COPD Treatment market?
Rising rates of chronic disease linked to diabetes, ageing, smoking and pollution, plus new treatments that slow disease, are driving the COPD Treatment market.
Who regulates COPD Treatment in New Zealand?
Medsafe, part of the Ministry of Health, approves medicines before they can be sold. Source: Medsafe. Checked 14 Nov 2026.
How is healthcare paid for in New Zealand?
Pharmac decides which medicines and medical devices the public health system pays for. Source: Pharmac. Checked 14 Nov 2026.
How many clinical trials on COPD Treatment are running in New Zealand?
9 studies are recruiting, active or about to start in New Zealand, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in New Zealand. Retrieved 12 Nov 2026.
How much research is published on COPD Treatment?
PubMed lists 399 papers on COPD Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in New Zealand

See all

Related on respiratory and smoking

See the topic